Cargando…
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are well-characterized, resistance patterns for dolutegravir (DTG),...
Autores principales: | Oliveira, Maureen, Ibanescu, Ruxandra-Ilinca, Anstett, Kaitlin, Mésplède, Thibault, Routy, Jean-Pierre, Robbins, Marjorie A., Brenner, Bluma G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098636/ https://www.ncbi.nlm.nih.gov/pubmed/30119633 http://dx.doi.org/10.1186/s12977-018-0440-3 |
Ejemplares similares
-
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014) -
HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017) -
HIV-1 strains belonging to large phylogenetic clusters show accelerated
escape from integrase inhibitors in cell culture compared with viral isolates from
singleton/small clusters
por: Brenner, Bluma G., et al.
Publicado: (2017) -
Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in “Real-World” Settings
por: Brenner, Bluma G., et al.
Publicado: (2017) -
Synthetic Approaches
to a Key Pyridone-carboxylic
Acid Precursor Common to the HIV-1 Integrase Strand Transfer
Inhibitors Dolutegravir, Bictegravir, and Cabotegravir
por: Mahajan, Pankaj S., et al.
Publicado: (2023)